First results of exagamglogene autotemcel in pediatric patients aged 5-11 years with transfusion-dependent β-thalassemia or sickle cell disease with recurrent severe vaso-occlusive crises

Abstract Background: Exagamglogene autotemcel (exa-cel) is a one-time, autologous cell therapy that reactivates fetal hemoglobin (HbF) synthesis via ex vivo CRISPR/Cas9 editing of autologous CD34+ hematopoietic stem and progenitor cells at the erythroid-specific enhancer region of BCL11A. Exa-cel is approved for individuals ≥12 years (y) old with transfusion-dependent β-thalassemia (TDT) or sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs). Based on exa-cel's mechanism of action, efficacy is expected to be similar across all ages. We report safety and efficacy data from the pediatric trials CLIMB THAL-141 and CLIMB SCD-151. Methods: CLIMB THAL-141 (TDT) and CLIMB SCD-151 (SCD) are ongoing 2-y, Phase 3 trials of exa-cel in participants (pts) aged 2-11 y with history of ≥100 mL/kg/y or ≥10 U/y of packed red blood cell (RBC) transfusions for 2 y before screening (TDT) or a history of ≥2 severe VOCs per y for 2 y before screening (SCD). Data for pts aged 5-11 y are reported. In CLIMB THAL-141 and CLIMB SCD-151, exa-cel was infused following PK-adjusted busulfan myeloablation. Pts are monitored for engraftment, total hemoglobin (Hb), HbF, allelic editing, transfusions, VOCs (SCD only), and adverse events (AEs). In CLIMB THAL-141, the primary endpoint is transfusion independence: proportion of pts maintaining a weighted average Hb ≥9 g/dL without RBC transfusion for ≥12 consecutive months (mo; TI12). In CLIMB SCD-151, the primary endpoint is proportion of pts free of severe VOCs for ≥12 consecutive mo (VF12); key secondary endpoint is proportion of pts free from inpatient treatment of severe VOCs for ≥12 consecutive mo (HF12). Upon completion of CLIMB THAL-141 or SCD-151, pts enroll in long-term trial CLIMB-131 for up to 15 y follow-up after exa-cel. Results: As of April 10, 2025, 13 TDT children <12 y (mean age 7.4 [range 5, 11] y; 61.5% male) and 10 SCD children <12 y (mean age 8.2 [range 5, 11] y; 50.0% male) received exa-cel. 5/13 (38.5%) TDT pts had β0/β0 or β0/β0-like genotypes and 12/13 had an intact spleen; all SCD pts had βS/βS genotype. All 13 TDT pts required ≤2 mobilization cycles (median 1.0 [range 1, 2]). 80% of SCD pts (8/10) required ≤2 mobilization cycles (median 2.0 [range 1, 3]). In CLIMB THAL-141, median follow-up after exa-cel was 12.6 (range 2.2, 22.7) mo. Pts achieved neutrophil (13/13) and platelet engraftment (11/13) at a median of 30 (range 19, 38) and 52 (range 22, 82) days, respectively. As of the datacut, 9/13 pts were transfusion-free and 5/5 pts evaluable for the primary efficacy endpoint achieved TI12, with the longest transfusion-free duration of 19.1 mo. Increases in total Hb and HbF were similar to that of adults and adolescents. Mean total Hb increased to ≥11.8 g/dL by Mo 6, which exceeds the age adjusted LLN, and was stable thereafter. Mean HbF increased to ≥11.0 g/dL by Mo 6 and was stable thereafter. In CLIMB SCD-151, median follow-up after exa-cel was 8.3 (range 3.9, 23.7) mo. All pts achieved neutrophil and platelet engraftment at a median of 28.5 (range 20, 37) and 45.5 (range 24, 67) days, respectively. No pts had VOCs after exa-cel infusion, with longest duration VOC-free of 20.7 mo. 2/2 evaluable pts achieved VF12 and HF12. Increases in HbF were similar to adults and adolescents. Mean HbF% >40% was achieved by Mo 6 and was durable with a pancellular distribution and normal total Hb. Pts with TDT and SCD had stable allelic editing in bone marrow and blood. The overall safety profile of exa-cel was consistent with myeloablative conditioning and autologous transplant in both TDT and SCD, as established in clinical trials of exa-cel for adolescents and adults. One pt in CLIMB THAL-141 developed severe veno-occlusive disease (VOD; related to busulfan, not related to exa-cel) with multi-organ failure that was fatal. VOD, including fatal VOD, is a known risk of busulfan therapy and is known to occur at higher frequency in children compared to adults. Conclusion: Efficacy and safety data for pts aged 5-11 y from CLIMB THAL-141 and CLIMB SCD-151 are consistent with data from exa-cel trials in pts aged ≥12 y. Exa-cel demonstrated clinical benefit in pediatric pts, with a safety profile consistent with busulfan myeloablative conditioning and autologous transplant. These data support exa-cel as a potential one-time functional cure for children aged 5-11 y with TDT and SCD, with potential additional benefit of treating early, prior to development of chronic disease complications.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.